Key facts
- Immune Algorithmics’s last known valuation is $34.4M (Sep 2025).
- It has raised $24.6M; the latest was Later Stage VC ($11.4M) in Sep 2025.
- Notable investors include Creative Destruction Lab, SFC Capital, University of Toronto, University of Toronto Entrepreneurship, Hub71 — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Immune Algorithmics
- ·The full record, as it builds
Funding rounds
No funding rounds for Immune Algorithmics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Immune Algorithmics
Developer of an immune monitoring platform designed to assist in blood analytics and remote health monitoring. The company's technology utilizes artificial intelligence to perform remote blood testing and assess the risk from home for a particular condition, enabling doctors to monitor their patient's health in an enhanced manner.
- Sector
- Healthcare
- HQ
- Reading, United Kingdom
- Founded
- 2018
- Employees
- 38
- Website
- immunealgorithmics.com/
- Ownership
- Privately Held (backing)
Immune Algorithmics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immune Algorithmics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immune Algorithmics in its N-PORT filings yet. We sweep new filings monthly.